Oppenheimer initiated coverage on Eupraxia Pharmaceuticals with a new price target
Stocks in this Quantisnow insightHealth Care
Historical context for EPRX
Across the 18 sessions after earlier EPRX headlines, the stock closed higher 12 times and lower 6 times, with a median move of 3.0% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | EPRX | SPY |
|---|---|---|---|
| Jun 22, 2026 | Eupraxia Pharmaceuticals Announces Voting Results from Annual General Meeting of Shareholders | +2.5% | -0.3% |
| May 28, 2026 | Eupraxia Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference | +2.8% | +0.6% |
| May 21, 2026 | Stifel initiated coverage on Eupraxia Pharmaceuticals with a new price target | +8.9% | +0.2% |
| May 13, 2026 | Eupraxia Pharmaceuticals Reports First Quarter 2026 Financial Results | -0.8% | +0.6% |
| May 6, 2026 | Eupraxia Pharmaceuticals' First Release of EoEHSS Sub Scores Data from its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis at Digestive Disease Week | +4.3% | +1.4% |
| May 5, 2026 | Eupraxia Pharmaceuticals Reports EREFS Data from its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis at Digestive Disease Week (DDW) | -2.0% | +0.8% |
Quantisnow market dataNASDAQ
EPRX
Eupraxia Pharmaceuticals Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Pharmaceuticals and Biotechnology
Get push alerts for EPRX
Full EPRX profile on Quantisnow Follow EPRX and get a push notification the moment its next story breaks.
Original source Picked up and delivered by Quantisnow in real time